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Severe traumatic brain injury (sTBI) is eas-
ily diagnosed by clinical examination and 
standard neuroimaging techniques. How-
ever, mild TBI (mTBI) or concussion (the 
two terms are used interchangeably in the 
literature), defined as a head trauma result-
ing in brief loss of consciousness and/or 
alteration of mental state [1], is much harder 
to objectively detect. Concussion causes no 
gross pathology, such as hemorrhage, and no 
abnormalities on a conventional computed 
tomography scan of the brain [1], but rather 
rapid-onset neuronal dysfunction that usu-
ally resolves over a few days to weeks. Pre-
sumably, exposure to head injury has been 
a feature of human existence for millennia, 
and the human brain has evolved normal 
adaptive and recovery processes.
A chronic syndrome, likely related to 
repetitive concussions, has not received much 
attention until recently. However, in 1928, 
Martland published a case series describ-
ing symptoms such as slowed movement, 
tremor, confusion and speech problems in a 
group of former boxers, which he called ‘the 
punch drunk syndrome’ [2]. A few years later, 
Millspaugh called this syndrome dementia 
pugilistica [3]. In 1973, Corsellis and col-
leagues published a case series in which the 
brains of 15 retired boxers were studied and 
the neuropathology of what we now know 
as chronic traumatic encephalopathy (CTE) 
was first described [4]. The molecular patho-
logy of this condition resembles aspects of 
Alzheimer’s disease, but with some distinc-
tions discussed below. Boxing was and still 
is the particular sport in which athletes vol-
untarily expose themselves to repetitive con-
cussion. However, a number of other sports, 
for example, American football, ice hockey, 
rugby and martial arts other than boxing, 
have now developed in such a way that pro-
fessional participation involves a considerably 
increased risk of repetitive concussions. More 
recently, case reports have shown patho-
logically confirmed CTE in contact sports 
athletes other than boxers and in former 
combat military personnel [5–7]. This has 
resulted in renewed interest in the potential 
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occur after concussive and subconcussive repetitive 
head trauma [8]. In addition to case reports showing 
pathology in ex-sportsmen, there is epidemiologic evi-
dence suggesting increased dementia risk after docu-
mented head injury [9], but apart from these types of 
descriptive studies there is a lack of systematic research 
on the problem.
Neuronal dysfunction in concussion is at least partly 
caused by direct damage to axons and other struc-
tures in the CNS. Approximately 15% of concussion 
patients suffer persisting cognitive dysfunction [10,11] 
and diffuse axonal injury (DAI) appears to be the most 
important underlying pathology in such cases [12]. 
The dysfunction may also relate to tau pathology that 
spreads around the brain in CTE [13,14]. However, 
what initiates this destructive and neurotoxic spread-
ing cascade only in some individuals and not others is 
unknown.
It is important to remember that head injury and 
concussion are not synonyms (one head injury may not 
impact the brain at all, whereas another, depending on 
how the mechanical forces of the head blow are trans-
ferred to the brain, may impact the brain profoundly), 
which may be a problem in epidemiological studies. It 
is also clear that different sports and other risk activi-
ties have different types of contact and, therefore, prob-
ably different types of lesion. What are the damaging 
types of lesion and what types of damage are revers-
ible and what are not reversible? How long does it take 
to recover from any particular type of damage? What 
are the outcomes of playing long-term professional 
sports today, when everything is faster, the players are 
heavier and the protective gear for the head appears 
less effective than protective gear for other parts of the 
body?
We now need systematic research on injury mecha-
nisms in concussion and how they relate to CTE. Fluid 
biomarkers in TBI may relate directly to brain injury, 
released principally from neurons, glia or blood ves-
sels or to response mechanisms such as microglial and 
astrocytic migration and activation, which may be pro-
tective or deleterious. Most individuals with concus-
sion do not develop CTE. However, in some individu-
als there may be a transition from an injury/recovery 
pattern to a persistent, progressive process represent-
ing the initiation of a neurodegenerative process and 
a transition to the earliest phases of CTE. We hypoth-
esize that this may relate to the extent, frequency and 
cumulative effect of brain injury together with varia-
tion in individual vulnerability to injury. It is possible 
that intrinsic (genetically determined) risk factors for 
Alzheimer’s, Parkinson’s or tauopathies such as pro-
gressive supranuclear palsy will also be risk factors for 
the development of CTE. Identification of individuals 
in the earliest phases of CTE is of crucial importance in 
terms of instituting appropriate advice on subsequent 
exposure, and in selecting individuals for future trials 
of disease-modifying therapies. Fluid biomarkers have 
the potential therefore to help to define: the severity of 
TBI; adaptive and recovery processes following TBI; 
and the transition between a normal injury/recovery 
pattern and a currently irreversible and inexorable 
CTE process. In this review, we start by discussing the 
different fluids that may be used as samples in which 
concussion biomarkers may be measured. We thereaf-
ter discuss technical aspects of the biomarker analysis. 
We then review the literature published so far on can-
didate biomarkers for concussion. Finally, we discuss 
the special case of CTE and emphasize the need for 
biomarker development for this disease entity.
Marker matrices 
Cerebrospinal fluid
Cerebrospinal fluid (CSF) is a clear fluid that sur-
rounds the brain, provides mechanical support and 
helps clear metabolites from the brain parenchyma 
together with direct transport across the blood–brain 
barrier, clearance via the glymphatic system and clear-
ance via the recently discovered meningeal lymphatic 
vessels [15,16]. The total CSF volume is approximately 
150 ml and the production and clearance rates are 
approximately 20 ml/h. Twenty to 30% of the CSF 
volume is derived directly from the brain; 70–80% 
is a choroid plexus-derived filtrate of plasma. CSF 
is sampled through a lumbar puncture, which is a 
harmless procedure with postlumbar puncture head-
ache as the sole potential complication [17]. Standard 
operating procedures for CSF sampling and handling 
have been established and the procedure can be done 
in outpatients [18]. The main advantage of CSF as a 
matrix in which to measure markers of CNS injury is 
that it communicates freely with the brain interstitial 
fluid that bathes the neurons. Biochemical changes 
in the brain are thus reflected in the CSF, which may 
be regarded as an accessible, although by no means 
perfect, sample of the brain interstitial fluid. Further, 
CSF has low protease activity and most molecules do 
not change upon sampling provided the sample is not 
contaminated by blood. The main disadvantage is that 
lumbar puncture may be regarded as impractical to 
perform in emergency settings and in clinical studies. 
Another limitation is that it is presently unclear how 
clearance of brain metabolites into the CSF relates to 
clearance via the glymphatic and/or lymphatic system 
of the brain; potentially, biomarkers we thought would 
be well reflected in the CSF may escape detection if 
their main clearance pathway is through these newly 
described systems directly into the blood.
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Blood
The other major biofluid for the measurement of con-
cussion markers is blood (serum or plasma). Blood is 
more accessible than CSF but most CNS-enriched 
markers are present in blood at very low concentrations 
that necessitate the employment of ultrasensitive tech-
niques that can measure in the femtomolar range (most 
standard immunochemical techniques cannot reach 
this analytical sensitivity). The blood–brain barrier also 
poses a challenge in the analysis of CNS injury markers 
in blood. Normally, the blood–brain barrier restricts the 
release of CNS-enriched proteins and peptides into the 
bloodstream and, for some molecules, specific transport 
mechanisms exist. In concussion, there may be a tran-
sient opening of the blood–brain barrier, which could 
increase the blood concentrations of CNS-enriched 
molecules, also in the absence of direct injury to the 
structures they are thought to represent. It may thus be 
difficult to tell to what extent a peak in the blood con-
centration of such a biomarker reflects CNS injury or 
blood-brain barrier damage/dysfunction. Reliable blood 
biomarkers for blood–brain biomarker integrity relat-
able to CNS injury markers would be a major contribu-
tion to the field (the best established biomarker so far for 
blood–brain barrier function is the CSF/serum albumin 
ratio, which obviously necessitates access to both body 
fluids [19]). Further, most intracellular proteins released 
into the bloodstream undergo degradation and/or mod-
ification by proteases and other enzymes and for most of 
the biomarker candidates discussed below, the normal 
half-life is unknown. The dilution of CNS proteins into 
4 l blood instead of 150 ml CSF may also contribute to 
the low concentrations of CNS-derived molecules in the 
blood.
Saliva, urine & tears
It is possible that some CNS-derived proteins are eventu-
ally excreted into body fluids other than CSF and blood. 
The presence of the axonal protein tau in saliva has been 
demonstrated using mass spectrometry [20]. The same 
research group has also detected Parkinson-related 
α-synuclein and DJ-1 in this body fluid [21]. However, 
the relationship between salivary concentrations of these 
proteins and processes within the CNS is far from clear 
and no conclusive data on disease association have been 
reported so far. Similar lines of reasoning are relevant 
to tears and urine, although renal clearance of poten-
tial concussion biomarkers may be a more physiological 
pathway than salivary or lacrimal clearance.
Measurement techniques
Most fluid markers of CNS injury are proteins or protein 
fragments that can be measured using immunochemical 
or MS-based techniques (or combinations thereof).
ELISA has become established as a standard method 
for the measurement of proteins in biofluids. The 
general principle is that a capture antibody directed 
against one epitope on the target analyte is immobi-
lized on a surface, whereafter sample and labeled detec-
tor antibody (directed against another epitope on the 
same analyte) are added sequentially between blocking 
and washing steps to remove unspecific signal. Cap-
ture and detector antibodies are in molar excess so that 
most of the target analyte is captured in a sandwich 
between the antibody pair. Many ELISAs and ELISA-
like techniques can reach lower limits of quantification 
of 10–100 pg/ml, but measuring even lower concentra-
tions, as is needed for most brain-specific proteins in 
the blood, is a challenge. Auto-antibodies against the 
target analyte or heterophilic antibodies (e.g., endog-
enous anti-mouse IgG antibodies) that may react 
with the antibodies in the assay may block epitopes or 
bridge the capture and detector antibodies (replacing 
the analyte), giving falsely low or high signals. Inter-
ference from heterophilic antibodies may be blocked 
using polyclonal mouse IgG or commercially available 
blockers.
To allow for ultrasensitive measurement, two new 
techniques have entered the market: Erenna and 
Simoa [22]. The magnetic bead-based Erenna system 
can detect molecules at femtogram/ml concentrations 
using Single Molecule Counting (SMC) technology 
in which labeled detector antibodies are released from 
the captured immunocomplexes and counted one 
by one. Simoa is based on the isolation of individual 
immunocomplexes on magnetic beads using standard 
ELISA reagents. The main difference between Simoa 
and conventional immunoassays lies in the ability to 
trap single beads in femtoliter volume wells. This com-
partmentalization of the detection reaction allows for 
a digital readout of each individual bead to determine 
if it has bound the target analyte or not. In theory, this 
type of assay thus measures at the single molecule level, 
which may also be true when using the SMC approach 
of Erenna. Another upcoming technique for ultrasen-
sitive biomarker quantification is proximity ligation 
assay, which builds on the principle that recognition 
of target proteins by two, three or more antibodies 
can bring in proximity DNA strands conjugated to 
the antibodies. The DNA strands can then participate 
in ligation reactions, giving rise to molecules that can 
undergo rolling circle amplification for highly sensi-
tive detection [23]. The same potential interferences 
as for ELISA, applies to these types of measurement 
techniques as well, as they are all antibody based.
MS-based explorative proteomics has been applied 
to discover novel biomarkers in complex samples such 
as CSF and plasma for many years. More recently, how-
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ever, antibody-independent selected or parallel reac-
tion monitoring (SRM or PRM)-based MS techniques 
have been developed for the quantitative measurement 
of proteins and protein fragments in a manner that is 
stable enough to allow for use on large sample series 
and in clinical laboratory practice [24]. SRM-based 
MS is a method that can be expected to grow into a 
complementary or alternative technique to immuno-
chemical assays in the analysis of protein markers in 
the near future [25].
Fluid markers of acute mild traumatic brain 
injury
Candidate fluid markers of acute mild TBI are 
summarized in Figure 1.
CSF markers
Axonal injury in concussion can be identified and moni-
tored using CSF levels of the intra-axonal proteins neuro-
filament light (NF-L) and tau [26,27], measured by ELISA. 
NF-L is a structural protein that is highly expressed in 
large-caliber myelinated axons that extend subcortically 
into deeper brain layers. These are the primary targets 
when a blow to the head applies rotational forces to the 
brain inducing DAI and NF-L leakage from injured 
axons into the CSF. After a boxing bout, NF-L concen-
trations in CSF correlate with the number of received 
head blows [26,27]. Similar results have been obtained 
using an assay for phosphorylated neurofilament heavy 
protein [28]. A recent case report on a knocked-out 
amateur boxer showed that it took 8 months before his 
CSF NF-L concentration normalized [29]. This result 
resonates with neuro pathological analyses showing that 
axonopathy can continue for years after TBI [30].
Tau is primarily expressed in thin unmyelinated 
axons and may respond more to cortical contusions than 
rotational brain injuries. However, CSF concentrations 
of tau change after both concussive and subconcussive 
head blows in a manner similar to NF-L but with a lower 
amplitude in the changes [27].
Figure 1. A neuron, an astroglial cell, a blood vessel and diffuse Aβ deposits close to a synapse. Candidate 
fluid biomarkers for concussion are indicated. NSE is a protein highly expressed in the neuronal soma, but also 
in red blood cells. UCHL1 is a de-ubiquitinating enzyme highly expressed in neurons, but also in gonads and 
lung tissue. α-SNTF is an axonal injury marker generated by the calpain family of calcium-activated proteases. 
SNTFs accumulate in the neuronal somaproximal part of injured axons following traumatic brain injury. NF-L 
and NF-H are intra-axonal structural proteins highly expressed in large-caliber axons. Tau is an intra-axonal 
structural protein highly expressed in thin, unmyelinated axons. S100B and GFAP are astroglial proteins. S100B is 
CNS-enriched but not specific, while GFAP appears to be highly CNS-specific. Aβ and other APP fragments may 
represent increased amyloidogenic APP-processing and diffuse plaque formation in response to axonal injury in 
traumatic brain injury. 








APP and Aβ fragments
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Studies in TBI models and on human brain tissue 
samples, as well as in brain interstitial fluid have dem-
onstrated that APP accumulates in neurons and axons 
after brain trauma with axonal damage and that there 
is release of amyloid β (especially aggregation-prone 
Aβ42) into brain interstitial fluid with plaque forma-
tion around damaged axons [31]. In spite of this, there 
are no clear changes in CSF levels of secreted APP or 
Aβ fragments in concussion [26,27].
Blood markers
In regard to blood biomarkers for concussion, recent 
data show promising results for tau, when measured 
on the ultrasensitive Simoa platform discussed above. 
A tau assay has been established on this platform and 
the first pilot studies have shown: a strong correlation 
between serum tau concentrations and neurological 
outcome in resuscitated cardiac arrest patients [32], 
increased tau concentrations in plasma from Olym-
pic boxers [33], increased tau concentrations in plasma 
from patients with Alzheimer’s disease [34], increased 
plasma tau concentrations in concussed ice hockey 
players 1 h after the injury; the degree of tau elevation 
correlated with the number of days it took until the 
players were free from symptoms [35]; and increased 
tau concentrations in plasma from military person-
nel who had been deployed within the previous 
18 months and reported or had medical records on 
having had a TBI [36]. The dynamics of tau changes in 
blood and CSF following acute brain injury appears 
to be distinct; tau levels in CSF and plasma do not 
correlate [34] and tau elevations following acute brain 
injury stay much longer in CSF (weeks) than in blood 
(days) [32,37]. Possibly, tau is degraded when entering 
the bloodstream. A recent study by Al Nimer et al. 
used conventional ELISA for detection of NF-L 
in serum of TBI patients, showing increased serum 
concentrations in patients with the most severe neu-
rotrauma [38]. The analytical sensitivity of the assay 
would, however, not allow for measuring serum NF-L 
in patients with mTBI or concussion and the corre-
lation with CSF NF-L concentrations was very low, 
in contrast to a recently published ultrasensitive assay 
based on the Simoa platform [39], which is now being 
examined in relation to TBI.
Another promising blood marker of concussion is 
the 1176 residue N-terminal fragment of α-spectrin, 
termed SNTF, which is a protein that accumulates 
preferentially in damaged axons [40]. SNTF is nor-
mally undetectable in axons, but is generated follow-
ing stretch injury by intra-axonal calcium overload and 
spectrin proteolysis mediated by the calpain family of 
calcium-activated proteases [41,42]. SNTF increases 
measurably in the blood after TBI, including CT- 
negative mTBI [43,44], and was recently found to be 
a predictive marker in sports-related concussion [45].
Other candidate blood biomarkers for brain injury 
in concussion include NSE, UCHL1, as well as the 
astroglia-enriched S100B and GFAP [46]. Clini-
cally relevant changes in serum concentrations for 
S100B [47] and GFAP [48] have been reported to detect 
radiographically apparent intracranial injury and the 
former protein has been included as a biomarker that 
could reduce the number of unnecessary CT scans of 
the brain in new clinical guidelines for the manage-
ment of head injury [47]. In contrast to tau and SNTF, 
none of these markers has a prognostic relationship 
with patient outcomes in concussion with negative 
brain computed tomography scan findings [46]. NSE, 
UCHL1 and S100B are also expressed in extracere-
bral tissues, which restricts their interpretability in 
multitrauma [46].
CTE
CTE is a neurodegenerative disease associated with 
repetitive head trauma [49]. Although initially believed 
to affect only boxers, the at-risk population has 
expanded to encompass a much wider demographic, 
including American football players, ice hockey play-
ers, wrestlers and military veterans. This expansion 
has garnered considerable media attention and public 
concern for the potential neurodegenerative effects of 
head trauma. There are no established autopsy-verified 
clinical criteria for CTE and no neuroimaging or fluid 
markers of the disorder, although the gross morpho-
logical changes seen in advanced CTE may be visual-
ized using standard neuroimaging techniques [50]. The 
molecular pathology of CTE is characterized by tau-
positive neurofibrillary tangles and neuropil threads 
that may be present in all regions of the brain with 
or without Aβ pathology [49]. Neurofibrillary tangles 
in CTE form preferentially in the superficial cortical 
layers, rather than in deeper layers as is more common 
in AD, with focal accumulations at the depths of the 
sulci [51]. Another distinctive feature is perivascular tau 
deposition [51].
In regards to in vivo markers of the molecular patho-
logy in CTE, preliminary findings from positron emis-
sion tomography (PET) scanning using PET ligands 
for brain tau in retired national football league players 
have recently been reported; five retired players were 
compared with five matched controls without a con-
cussion history and displayed higher overall signals of 
tau deposition in their brains [52]. Amyloid PET imag-
ing in traumatic brain injury has yielded ambiguous 
data, possibly due to the diffuse nature of trauma-
related Aβ deposits that are less prone to bind amyloid 
ligands than neuritic plaques [53].
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No data on fluid markers of tau and Aβ pathology 
have been presented so far but clinical biomarker studies 
with longitudinal follow-up of patients with chronic or 
progressive symptoms after TBI, for example, the Diag-
nosing and Evaluating Traumatic Encephalopathy using 
Clinical Tests (DETECT) study [54], are in progress and 
will tell us more about the pathogenesis, risk factors and 
clinical course of CTE, and how CTE can be diagnosed 
and monitored with the help of biomarkers.
Could markers of mild TBI/concussion help 
prevent CTE?
The primary goal of biomarker research in TBI is not 
to develop techniques to identify moderate to severe 
brain injury, as such already exist, but rather to iden-
tify molecular changes in mTBI/concussion to indicate 
if the brain was injured by a head injury and to monitor 
the recovery process. Most current research suggests that 
the risk of long-term symptoms following concussion is 
highest in individuals who have received repetitive con-
cussions before the brain has recovered properly [49]. 
Identifying incomplete recovery following concussion 
using an objective test and prolong the rehabilitation 
phase in such cases could potentially help to reduce the 
incidence of CTE.
Conclusion & future perspective
Several promising CSF and blood markers of concus-
sion exist but the field is not yet mature enough to rank 
them according to diagnostic accuracy. Their potential 
predictive value in regard to time to complete recovery 
and risk of incomplete recovery/CTE needs to be estab-
lished. Further, we need more knowledge on release and 
clearance mechanisms of the candidate biomarkers and 
how their blood concentrations relate to blood–brain 
barrier dysfunction. Another outstanding research ques-
tion is if additional information could be gained by com-
bining different markers with each other, for example, 
by quantifying the extent of both the axonal injury and 
the inflammatory response using different biomarker 
combinations. All this should be relevant not only for 
sports-related concussions but also for the many con-
cussions that are not sports related. Information gained 
using biomarkers for TBI could potentially be used to 
identify at-risk cases most appropriate for enrollment in 
clinical research studies and therapeutic trials.
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